Supercharge Your Innovation With Domain-Expert AI Agents!

Method for treating herpes virus infection

A herpes virus infection and herpes virus technology, applied in antiviral agents, pharmaceutical formulas, medical preparations of non-active ingredients, etc., can solve problems such as low solubility and difficult realization of diclofenac aqueous injection solutions

Inactive Publication Date: 2012-10-03
YUNG SHIN PHARMACEUTICALS INDUSTRIAL CO LTD +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Aqueous injection solutions of diclofenac are difficult to achieve due to its relatively low solubility in water

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating herpes virus infection
  • Method for treating herpes virus infection
  • Method for treating herpes virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Embodiment 1. Preparation of emulsion formula

[0033] The emulsion carrier ± [active ingredient] is prepared by the following steps:

[0034] 1. Preparation of the oil phase: Immerse the mixing vessel in a hot water bath (80±2°C). [Acyclovir, 50g] methylparaben (1g), propylparaben (1g), cetyl alcohol (60g), sorbitan monostearate 60 (12g), hard Fatty acid (steric acid) (20g), synthetic spermaceti (50g), dimethyl polysiloxane (30g), and triglyceride caprylic-capric acid ester (miglyol) 812 (70g) add this mixing vessel and stir to Mix well. The mixture was filtered once through a 150 mesh screen to remove particulates.

[0035] 2. Preparation of the aqueous phase: Immerse another mixing vessel in a hot water bath (80±2°C). [Diclofenac sodium salt, 50g] [Diclofenac lidocaine salt, 10g, 30g, or 50g] polysorbate 60 (36g), propylene glycol (160g), sodium citrate (10g), and sufficient to make the total weight reach 1000 g of pure water was added to the mixing vessel and s...

Embodiment 2

[0038] Example 2. Testing different compounds on animals

[0039] Target:

[0040] Test (1) ADO-1, ADO-2, ADO-3, and ADO-4 on herpes animal model; (2) 1% VDO99 emulsion, 3% VDO99 emulsion, 5% VDO99 emulsion and their placebo; ( 3) Effect of VGO99 emulsion (diclofenac sodium, 50 mg (RA009)), VDO99 emulsion (diclofenac, lidocaine salt 50 mg (RA052)), VAO99 emulsion (lidocaine, 50 mg (RA001)) and their placebo emulsions. The emulsion formulation ± active ingredient was prepared according to Example 1.

[0041] Test compound:

[0042] Group I

[0043] ADO-1: 5% acyclovir (50mg / g) plus 5% diclofenac lidocaine salt (Lidofenac50mg / g)

[0044] ADO-2: 5% acyclovir (50mg / g)

[0045] ADO-3: 5% diclofenac lidocaine salt (Lidofenac 50mg / g)

[0046] ADO-4: Vector.

[0047] Group II

[0048] 1% VDO99 emulsion: diclofenac, lidocaine salt (Lidofenac 10mg / g, RA032);

[0049] VDO99 placebo emulsion (RA035 placebo);

[0050] 3% VDO99 emulsion: diclofenac, lidocaine salt (Lidofenac 30mg / ...

Embodiment 3

[0122] Example 3. Clinical research protocol

[0123] Target:

[0124] To evaluate the effectiveness of VGO99 (5% diclofenac sodium emulsion) in patients with herpes zoster. The efficacy is judged by intensity ratings of pain and lesions.

[0125] study endpoint

[0126] Evaluate the following endpoints

[0127] · The primary efficacy endpoint was the time to complete cessation of shingles-related pain. Subjects were defined as achieving complete cessation of pain if they were pain-free for at least 7 days (pain reported as 0 on a numerical scale of 0-100).

[0128] Time to cessation of acute phase pain (pain experienced until all crusts fall off)

[0129] • A rough rate of subjects achieving complete cessation of shingles-related pain at the end of the follow-up period.

[0130] • Rough rate of subjects free of blisters, ulcers and crusts at the end of the treatment period and follow-up period.

[0131] • Percent reduction in VAS pain scores at specific clinical visits...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is directed to a method for inhibiting herpes viral activity in a subject, by administering to the subject in need thereof an active ingredient consisting essentially of an effective amount of diclofenac (for example, 3-7% w / v) or a pharmaceutically acceptable salt thereof.

Description

technical field [0001] The present invention relates to a method of inhibiting the activity of a herpes virus in a subject in need thereof by administering to the subject an active ingredient consisting essentially of an effective amount of diclofenac or a pharmaceutically acceptable salt thereof. Background technique [0002] Herpesviruses comprise a large class of double-stranded DNA viruses. Herpesvirus species can be divided into three subfamilies (ie, α, β, and γ) based on a number of biological characteristics such as host range and tropism, viral life cycle, and viral persistence and latency. Eight herpes viruses, herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella zoster virus (VZV), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and Human herpesviruses 6, 7, and 8 (HHV-6, HHV-7, and HHV-8) have been shown to infect humans. [0003] Among these herpes viruses, two commonly known are herpes simplex virus types 1 and 2, known as HSV1 and HSV2, an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/195A61K31/047A61P31/22
CPCA61K47/14A61K31/196A61K47/26A61K47/10A61K9/0014A61K9/107A61K9/06A61K47/34A61P31/12A61P31/22A61K31/195A61K31/047
Inventor 李芳全谢慧玲
Owner YUNG SHIN PHARMACEUTICALS INDUSTRIAL CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com